力生製藥(002393.SZ):子公司中央藥業藥品鹽酸維拉帕米片通過仿製藥一致性評價
格隆匯4月22日丨力生製藥(002393.SZ)公佈,近日,公司的子公司天津市中央藥業有限公司(“中央藥業”)收到國家藥品監督管理局頒發的關於鹽酸維拉帕米片40mg規格的《藥品補充申請批件》(批件號:2020B02655),該藥品通過仿製藥質量和療效一致性評價,中央藥業為全國首家通過該品種一致性評價的企業。
鹽酸維拉帕米片,適應症為:1.心絞痛:變異型心絞痛,不穩定性心絞痛,慢性穩定性心絞痛。2.心律失常:與地高辛合用控制慢性心房顫動和/或心房撲動(除WPW綜合徵或L-G-L綜合徵外)時的心室率,預防陣發性室上性心動過速的反覆發作。3.原發性高血壓。
中央藥業該藥品通過仿製藥質量和療效一致性評價,有利於提升該藥品市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.